Associations of pre-HCT CMV reactivation (with or without clearance after preemptive antiviral therapy) and of last pre-HCT CMV DNA PCR test result with the risk of post-HCT CMV reactivation at multiple levels. Multivariable Cox regression of the risk of post-HCT CMV reactivation associated with the absence or presence of pre-HCT CMV with or without clearance after preemptive antiviral therapy (above demarcation line in each plot, as circles) or by the last pre-HCT CMV PCR test (below demarcation line in each plot, as diamonds). Evaluated post-HCT CMV end points include any level (A), ≥150 IU/mL (B), or ≥500 IU/mL (C). ˆReference (ie, no CMV detection within 7-90 days before HCT) includes a small number of patients with pre-HCT CMV reactivation ≥50 and <150 IU/mL who became negative before HCT without preemptive antiviral therapy (n = 17). ⁼Indicates inclusion of patients with pre-HCT CMV reactivation ≥50 IU/mL who received preemptive antiviral therapy and became negative before HCT. ^#Indicates inclusion of patients with pre-HCT CMV reactivation ≥50 IU/mL who received preemptive antiviral therapy and did not become negative before HCT. Models were also adjusted for recipient age, race, underlying disease, HCT-CI score, transplantation year, donor CMV serostatus, HLA matching, GVHD prophylaxis, and acute GVHD grade (time-dependent variable). 95% CI, 95% confidence interval.